Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Suthinee, Ithimakin"'
Autor:
Thanate Dajsakdipon, Thiti Susiriwatananont, Concord Wongkraisri, Suthinee Ithimakin, Napa Parinyanitikul, Archara Supavavej, Arunee Dechaphunkul, Patrapim Sunpaweravong, Sunee Neesanun, Charuwan Akewanlop, Thitiya Dejthevaporn, TSCO Breast Oncology Group
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background The current standard first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR + /HER2 −) advanced breast cancer (ABC) is a combination of aromatase inhibitor (AI) plus CDK4/6 inhib
Externí odkaz:
https://doaj.org/article/5b0a3d9bcc4b42bca28dd69de26ddc68
Autor:
Thikhamporn Tawantanakorn, Thawatchai Akaraviputh, Vitoon Chinswangwatanakul, Suthinee Ithimakin, Janjira Petsuksiri, Atthaphorn Trakarnsanga
Publikováno v:
Siriraj Medical Journal, Vol 75, Iss 4 (2023)
Objective: The current standard of care for locally advanced rectal cancer is associated with multimodality therapy. Neoadjuvant chemoradiation significantly decreased the locoregional recurrence rate and improved survival. However, distant metastasi
Externí odkaz:
https://doaj.org/article/195ccd18dd984e57bad75b8026182369
Autor:
Tanun Jitwatcharakomol, MD, Jiraporn Setakoranukul, MD, Suthinee Ithimakin, MD, Rungroj Krittayaphong, MD, Kullathorn Thephamongkhol, MD
Publikováno v:
Advances in Radiation Oncology, Vol 8, Iss 1, Pp 101072- (2023)
Purpose: Internal mammary lymph node radiation therapy (IMN-RT) has unclear benefits. Historical data were based on only conventional (2-dimensional) radiation techniques. In this 3-dimensional radiation therapy era, we compared the distant metastasi
Externí odkaz:
https://doaj.org/article/fcf7081fb882447bb0a750c4a79bc316
Autor:
Nuttapong Ngamphaiboon, Suthinee Ithimakin, Teerada Siripoon, Nattaya Sintawichai, Virote Sriuranpong
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Most immune-related adverse event (irAE) patterns and treatment guidelines are based on western clinical data. We evaluated the incidence and patterns of irAEs in patients treated with immune-checkpoint inhibitors (ICI) in Thailan
Externí odkaz:
https://doaj.org/article/fb17b7216d0644f4989caa98b9fbf9db
Publikováno v:
Asian Pacific Journal of Cancer Prevention. 24:1359-1366
Autor:
Rochanawan Sootichote, Peti Thuwajit, Ekapot Singsuksawat, Malee Warnnissorn, Pa-thai Yenchitsomanus, Suthinee Ithimakin, Jomjit Chantharasamee, Chanitra Thuwajit
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-12 (2018)
Abstract Background Paclitaxel (PTX) is a potent anti-cancer drug commonly used for the treatment of advanced breast cancer (BCA) and melanoma. Toll-like receptor 4 (TLR4) promotes the production of pro-inflammatory cytokines associated with cancer c
Externí odkaz:
https://doaj.org/article/2aee8ea728df4847bf6cab5f5abcb3c7
Autor:
Max S. Wicha, Hasan Korkaya, Daniel F. Hayes, Dafydd G. Thomas, Celina G. Kleer, Mark L. Day, Whitney A. Chadwick, Shawn G. Clouthier, Tahra K. Luther, Nader Tawakkol, Amber N. Heath, Nallasivam Palanisamy, Christopher L. Hall, April Davis, Stephanie Daignault, Kathleen Woods Ignatoski, Ahmed A. Quraishi, Tom F. Bersano-Begey, Scott J. Dawsey, Qin Zen, Fayaz Malik, Kathleen C. Day, Suthinee Ithimakin
PDF file - 491K, Supplementary Figure 3. Effect of trastazumab on stem cell marker expression. Supplementary Figure 2. Trastuzumab inhibits tertiary tumorsphere formation in luminal cell lines. Supplementary Figure 1. Representative FACS analysis dem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::560abdc1fd7d537096d1f2568089c598
https://doi.org/10.1158/0008-5472.22400423.v1
https://doi.org/10.1158/0008-5472.22400423.v1
Autor:
Kittinut Timudom, Natthawut Phothong, Thawatchai Akaraviputh, Vitoon Chinswangwatanakul, Ananya Pongpaibul, Janjira Petsuksiri, Suthinee Ithimakin, Atthaphorn Trakarnsanga
Publikováno v:
Gastroenterology Research and Practice, Vol 2016 (2016)
Background. Traditionally, rectal cancer surgery is recommended 6 to 8 weeks after completing neoadjuvant chemoradiation. Extending the waiting time may increase the tumor response rate. However, the perioperative complication rate may increase. The
Externí odkaz:
https://doaj.org/article/f2ea2e8bf3104a4ea47dd33f29817957
Autor:
Daniela Kolarevic Ivankovic, Rob H.A. Verhoeven, Suthinee Ithimakin, Jorge Barriuso, Antonio Calles, Ivana Bozovic-Spasojevic, Charlotte I. Stroes, Martijn G H van Oijen, Carlos Gomez-Roca, Andrew Furness, Wan-Ling Tan, Willemieke P M Dijksterhuis, H. Laarhoven, Sjoukje F. Oosting
Publikováno v:
International Journal of Cancer
Dijksterhuis, W P M, Stroes, C I, Tan, W-L, Ithimakin, S, Calles, A, van Oijen, M G H, Verhoeven, R H A, Barriuso, J, Oosting, S F, Korarevic Ivankovic, D, Furness, A J S, Bozovic-Spasojevic, I, Gomez-Roca, C & van Laarhoven, H W M 2019, ' From presentation to paper: gender disparities in oncological research ', International Journal of Cancer . https://doi.org/10.1002/ijc.32660
International Journal of Cancer, 37(15). Wiley
International journal of cancer. Journal international du cancer, 146(11), 3011-3021. Wiley-Liss Inc.
Dijksterhuis, W P M, Stroes, C I, Tan, W-L, Ithimakin, S, Calles, A, van Oijen, M G H, Verhoeven, R H A, Barriuso, J, Oosting, S F, Korarevic Ivankovic, D, Furness, A J S, Bozovic-Spasojevic, I, Gomez-Roca, C & van Laarhoven, H W M 2019, ' From presentation to paper: gender disparities in oncological research ', International Journal of Cancer . https://doi.org/10.1002/ijc.32660
International Journal of Cancer, 37(15). Wiley
International journal of cancer. Journal international du cancer, 146(11), 3011-3021. Wiley-Liss Inc.
Gender disparities in scientific publications have been identified in oncological research. Oral research presentations at major conferences enhance visibility of presenters. The share of women presenting at such podia is unknown. We aim to identify
Autor:
Apirom Laocharoenkiat, Suthinee Ithimakin, Pathra Theeratrakul, Sirisopa Techawattanawanna, C. Akewanlop, Krittiya Korphaisarn, Akarin Nimmannit, Nopadol Soparattanapaisarn, P. Danchaivijitr
Publikováno v:
Supportive Care in Cancer. 28:5335-5342
We assessed the efficacy of aprepitant (APR) or 10 or 5 mg OLN (OLN10 or OLN5) plus ondansetron and dexamethasone for chemotherapy-induced nausea/vomiting (CINV) prophylaxis in patients receiving high-emetogenic chemotherapy (HEC). Patients who recei